Simple Predictor In Scleroderma Related Interstitial Lung Disease PDF Print E-mail
Tuesday, 23 October 2012 23:18
Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.

Patients classified as having “extensive” (> 20%) lung disease as seen on an HRCT-lung  scan were three times more likely to die, need supplementary oxygen or a lung transplant, the authors wrote in Rheumatology.

Baseline HRCT-lung scans were available for 172 patients, who were followed for a mean of 3.5 years, with 30 experiencing an adverse outcome.

The level of lung disease identified on the scans was graded as ‘extensive’ (>20%), ‘limited’ (<20%) or ‘indeterminate’. Those classified as ‘indeterminate’ were allocated to either extensive or limited by looking at forced vital capacity, the authors said.

“I think it’s very important to have a HRCT-lung [scan] to confirm the diagnosis of interstitial lung disease in patients with Scleroderma,” author Dr Mandana Nikpour of the University of Melbourne and St Vincent’s Hospital Melbourne told Rheumatology Update.

“What we have confirmed is that there is an added value in that enables one to prognosticate as well.”

However Dr Nikpour did not recommend serial HRCT-lung scans because of the radiation exposure and cost and said that performing serial pulmonary function tests was a better way to track changes over time.

Saying that their grading system was “simple and quick” the authors proposed “the routine use of this HRCT grading system to obtain prognostic information in patients with SSc-ILD.”

Source: Pain, C (2012), "Simple predictor in systemic sclerosis-related ILD"; Rheumatology Update; Original article can be viewed here.

 
More articles :

» Chinese Medicine Used In The Treatment Of Scleroderma

According to many proponents of eastern medicine, Chinese medicine is a whole holistic system that can lead to a healthier, happier and more stress free way of living. It is a system that people have benefited from for over twenty-three centuries...

» Actelion Pharmaceuticals Announces Commercial Availability Of Epoprostenol For Injection For The Treatment Of Pulmonary Arterial Hypertension

Actelion Pharmaceuticals US, Inc. today  announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and...

» Quality Indicator Sets For Scleroderma

Despite the increasing awareness of Scleroderma (SSc), it continues to have a detrimental effect of the quality of health and lives of those with it. The medical community has recognized that although early treatment of can have a substantial...

» Quality Indicator Set for Systemic Sclerosis

D. Khanna, O. Kowal-Bielecka, P.P. Khanna, A. Lapinska, S.M. Asch, N. Wenger, K.K. Brown, P. Clements, T. Getzug, M.D. Mayes, T.A. Medsger Jr., R. Oudiz, R. Simms, V. Steen, P. Maranian, D.E. FurstBackground:Systemic sclerosis (SSc) is associated...

» New Promising Therapy Against Systemic Sclerosis

There is a new path to defeat systemic sclerosis, also called because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent...

» Joint Involvement And Aggressive Systemic Sclerosis

Clinical joint involvement is strikingly common in patients with systemic sclerosis () and is associated with a more active and severe disease phenotype, according to an analysis of the world’s largest systemic sclerosis (SSc) registry. proved to...